Clinical Trial: Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765966) titled 'Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias' on Aug. 10.

Brief Summary: The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.

Study Start Date: Feb. 01, 2027

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Autoimmune Cytopenias Immune Thrombocytopenia (ITP)

Intervention: BIOLOGICAL: RXIM002

Targeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)

Recruitment Status: NOT_YET_RECRUITING

Spon...